Back to top Open menu arrow
The Journal of Clinical Psychiatry The Journal of Clinical Psychiatry

The Journal of
Clinical Psychiatry
Access icon

This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands
  2. PsyQ Haaglanden, Parnassia Psychiatric Institute, The Hague, the Netherlands
  3. Corresponding author: Jolien K. E. Veraart, MD, Mangostraat 1, 2552 KS The Hague, the Netherlands ([email protected]).
  4. University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands
  5. Pro Persona Mental Health Care, Depression Expertise Center, Nijmegen, the Netherlands
  6. Radboud University Nijmegen, the Netherlands eUniversity of Groningen, Research School of Behavioural and Cognitive Neurosciences (BCN), Groningen, the Netherlands
  7. University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands
  8. University of Groningen, University Medical Center Groningen, Department of Psychiatry, Groningen, the Netherlands
  9. University of Groningen, Research School of Behavioural and Cognitive Neurosciences (BCN), Groningen, the Netherlands
  1. Jonkman K, Dahan A, van de Donk T, et al. Ketamine for pain. F1000 Res. 2017;20(6):F1000.
  2. Khorramzadeh E, Lotfy AO. The use of ketamine in psychiatry. Psychosomatics. 1973;14(6):344–346. PubMed CrossRef
  3. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351–354. PubMed CrossRef
  4. Han Y, Chen J, Zou D, et al. Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatr Dis Treat. 2016;12:2859–2867. PubMed CrossRef
  5. Papakostas GI, Salloum NC, Hock RS, et al. Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry. 2020;81(4):19r12889. PubMed CrossRef
  6. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. PubMed CrossRef
  7. Short B, Fong J, Galvez V, et al. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018;5(1):65–78. PubMed CrossRef
  8. Lai R, Katalinic N, Glue P, et al. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry. 2014;15(7):579–584. PubMed CrossRef
  9. Loo CK, Gálvez V, O’Keefe E, et al. Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand. 2016;134(1):48–56. PubMed CrossRef
  10. Farmer CA, Gilbert JR, Moaddel R, et al. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology. 2020;45(8):1398–1404. PubMed CrossRef
  11. Javitt DC, Doneshka P, Zylberman I, et al. Impairment of early cortical processing in schizophrenia: an event-related potential confirmation study. Biol Psychiatry. 1993;33(7):513–519. PubMed CrossRef
  12. Lodge D, Mercier MS. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254–4276. PubMed CrossRef
  13. Carpenter WT Jr. The schizophrenia ketamine challenge study debate. Biol Psychiatry. 1999;46(8):1081–1091. PubMed CrossRef
  14. Bubeníková-Valesová V, Horácek J, Vrajová M, et al. Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. Neurosci Biobehav Rev. 2008;32(5):1014–1023. PubMed CrossRef
  15. Winship IR, Dursun SM, Baker GB, et al. An overview of animal models related to schizophrenia. Can J Psychiatry. 2019;64(1):5–17. PubMed CrossRef
  16. Jääskeläinen E, Juola T, Korpela H, et al. Epidemiology of psychotic depression - systematic review and meta-analysis. Psychol Med. 2018;48(6):905–918. PubMed CrossRef
  17. Charney DS, Nelson JC. Delusional and nondelusional unipolar depression: further evidence for distinct subtypes. Am J Psychiatry. 1981;138(3):328–333. PubMed CrossRef
  18. Conley RR, Ascher-Svanum H, Zhu B, et al. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007;90(1-3):186–197. PubMed CrossRef
  19. Dutta R, Murray RM, Allardyce J, et al. Early risk factors for suicide in an epidemiological first episode psychosis cohort. Schizophr Res. 2011;126(1-3):11–19. PubMed CrossRef
  20. Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519–534. PubMed CrossRef
  21. Krynicki CR, Upthegrove R, Deakin JFW, et al. The relationship between negative symptoms and depression in schizophrenia: a systematic review. Acta Psychiatr Scand. 2018;137(5):380–390. PubMed CrossRef
  22. Strassnig MT, Raykov T, O’Gorman C, et al. Determinants of different aspects of everyday outcome in schizophrenia: the roles of negative symptoms, cognition, and functional capacity. Schizophr Res. 2015;165(1):76–82. PubMed CrossRef
  23. Helfer B, Samara MT, Huhn M, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(9):876–886. PubMed CrossRef
  24. Lally N, Nugent AC, Luckenbaugh DA, et al. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4(10):e469. PubMed CrossRef
  25. Ishihara H, Kudo H, Murakawa T, et al. Uneventful total intravenous anaesthesia with ketamine for schizophrenic surgical patients. Eur J Anaesthesiol. 1997;14(1):47–51. PubMed CrossRef
  26. Lahti AC, Weiler MA, Tamara Michaelidis BA, et al. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25(4):455–467. PubMed CrossRef
  27. Pennybaker SJ, Luckenbaugh DA, Park LT, et al. Ketamine and psychosis history: antidepressant efficacy and psychotomimetic effects postinfusion. Biol Psychiatry. 2017;82(5):e35–e36. PubMed CrossRef
  28. Medeiros da Frota Ribeiro C, Sanacora G, Hoffman R, et al. The use of ketamine for the treatment of depression in the context of psychotic symptoms: to the editor. Biol Psychiatry. 2016;79(9):e65–e66. PubMed CrossRef
  29. Medeiros da Frota Ribeiro C, Sanacora G, Ostroff R. Reply to: ketamine and psychosis history: antidepressant efficacy and psychotomimetic effects postinfusion. Biol Psychiatry. 2017;82(5):e37. PubMed CrossRef
  30. Ajub E, Lacerda ALT. Efficacy of esketamine in the treatment of depression with psychotic features: a case series. Biol Psychiatry. 2018;83(1):e15–e16. PubMed CrossRef
  31. Zarrinnegar P, Kothari J, Cheng K. Successful use of ketamine for the treatment of psychotic depression in a teenager. J Child Adolesc Psychopharmacol. 2019;29(6):472–473. PubMed CrossRef
  32. Bartova L, Papageorgiou K, Milenkovic I, et al. Rapid antidepressant effect of S-ketamine in schizophrenia. Eur Neuropsychopharmacol. 2018;28(8):980–982. PubMed CrossRef
  33. Ye J, Lin X, Jiang D, et al. Adjunct ketamine treatment effects on treatment-resistant depressive symptoms in chronic treatment-resistant schizophrenia patients are short-term and disassociated from regional homogeneity changes in key brain regions: a pilot study. Psychiatry Clin Psychopharmacol. 2019;29(4):907–915. CrossRef
  34. Zhuo CA-OX, Lin X, Tian H,et al. Adjunct ketamine treatment of depression in treatment-resistant schizophrenia patients is unsatisfactory in pilot and secondary follow-up studies. 2020;10(5):e01600.
  35. Nunes MV, Adelino MPM, Ajub E, et al. Efficacy of esketamine in the treatment of negative symptoms in schizophrenia: a case series. Schizophr Res. 2018;202:394–396. PubMed CrossRef
  36. Ostroff R, Gonzales M, Sanacora G. Antidepressant effect of ketamine during ECT. Am J Psychiatry. 2005;162(7):1385–1386. PubMed CrossRef
  37. Grott Zanicotti C, Perez D, Glue P. Case report: long-term mood response to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med. 2013;16(7):719–720. PubMed CrossRef
  38. Krystal JH, D’Souza DC, Karper LP, et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl). 1999;145(2):193–204. PubMed CrossRef
  39. Shcherbinin S, Doyle O, Zelaya FO, et al. Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects. Psychopharmacology (Berl). 2015;232(21–22):4191–4204. PubMed CrossRef
  40. Malhotra AK, Adler CM, Kennison SD, et al. Clozapine blunts N-methyl-d-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry. 1997;42(8):664–668. PubMed CrossRef

Save Save

Share Share

Cite Cite

Read the Current Issue

Vol 85, 2024 3

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

SSRI Discontinuation and AUD Relapse

Reproductive Pharmacovigilance and Best Practices

Olanzapine and Mirtazapine for Cancer-Related Anorexia

Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia

Functional Unblinding in Pivotal Studies and the Future of Psychedelic Medicine
View current Issue

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe